Famotidine and COVID-19

Phase 3

Recruiting

• Conditions: aboratory confirmed COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200509047364N2
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

All COVID-19 patients whose disease has been confirmed by the PCR test for SARS-Cov-2.
Signing the written consent of the study participant.

Exclusion Criteria

All Immunocompromised patients
End stage renal disease
Moderate renal insufficiency (creatinine clearance 30-50 mL/min)
stage 4 sever chronic kidney disease
requiring dialysis (i.e creatinine clearance <30 mL/min)
History of hepatic disease
History of hepatitis C infection
History of alcoholism
G-6-PD (glucose-6-phosphate dehydrogenase deficiency)
ALT/AST >5 times the upper limit of normal.
History of or evidence of QT prolongation on ECG examination
History of psoriasis
History of porphyria
Pregnancy
Use of oral contraceptive pills (OCP)
Concomitant use of Dasatinib
Concomitant use of Neratinib
Concomitant use of Ozanimod
Concomitant use of Pazopanib
Concomitant use of Rilpivirine
Concomitant use of Siponimod
Concomitant use of Tizanidine
Allergy to any study medication

Study & Design

• Study Type: interventional
• Study Design: Not specified